|
Drug Information
Pharmacokinetics
| Indication
& Dosage | Action
| Interaction |
Adverse
Effects & Precautions | Brands
Available in Market
Pharmacokinetics
It is completely absorbed from the GIT and is primarily
metabolised in the liver and excreted by the kidney in the urine.
Oral
ATRIAL AND VENTRICULAR TACHYARRYTHMIAS, ECTOPIC BEATS: Usually 100-300mg
orally daily. May be doubled if required. Children: 25-100mg/day
according to age.
A class 1-A antiarrythmic. Reduces rate of depolarisation phase of cardiac action potential, slow depolarisation and prolongs refractory period. Exert vagal blockade, controls atrial fibrillation, ventrucular and supra-ventrucular tachycardias.
With Anticoagulants : Risk of bleeding may be increased. Digoxin: cardiac effects may be increased. Pimozide : Risk of cardiac arrhythmias may be increased. Urinary alkalizers: such as acetazolamide, calcium or magnesium-containing antacids, dichlorphenamide, methazolamide, potassium or sodium citrate or citric acid, sodium bicarbonate: Effects of the drug may be potentiated because levels of quinidine in the body may be increased.
It has low therapeutic ratio. Cardiotoxicity- S.A block or arrest, high
grade A.V. block, ventricular asstole, polymorphic ventricular
tachyarrhythmia. Hypotension (particularly when given I.V.), Cinchonism,
Tinnitus, loss of haearing, gastrointestinal upset, severe headace,
diplopia, photophobia, altered colour perception, confusion, delirium
and psychosis, hot and flushed skin, nausea, vomiting, diarrhoea,
abdominal pain, fever, anaphylactic reaction, thrombocytopienia.
Precaution to be taken are in Asthma or emphysema:
Possible allergic reaction. Blood disorders, Infection, renal disease or
hepatic disease: Effects may be potentiated because of slower removal of
quinidine from the body. Myasthenia gravis: Muscle weakness may be
increased. Precuations must alos be taken in hyperthyroidism and
psoriasis.
